177 related articles for article (PubMed ID: 9636479)
21. Tolerability of mycophenolate mofetil in organ transplant recipients.
Schweizer RT; Meisterling LD
Transplant Proc; 2001 May; 33(3):2309. PubMed ID: 11377540
[No Abstract] [Full Text] [Related]
22. Pharmacokinetics of mycophenolate mofetil in eight pediatric renal transplant patients.
Aigrain EJ; Shaghaghi EK; Baudouin V; Popon M; Loirat C
Transplant Proc; 2000 Mar; 32(2):388-90. PubMed ID: 10715449
[No Abstract] [Full Text] [Related]
23. Mycophenolate: better value through monitoring?
Tredger JM; Brown NW
Transplantation; 2006 Feb; 81(4):507-8. PubMed ID: 16495794
[No Abstract] [Full Text] [Related]
24. High mycophenolic acid area under-the-curve values in renal transplant recipients on long-term mycophenolate mofetil treatment.
Engelbertink R; Smak Gregoor P; Hesse C; IJzermans J; Weimar W; van Gelder T
Transplant Proc; 2002 Nov; 34(7):2983-4. PubMed ID: 12431677
[No Abstract] [Full Text] [Related]
25. Determination of mycophenolic acid level: comparison of high-performance liquid chromatography with homogeneous enzyme-immunoassay.
Yeung JS; Wang W; Chan L
Transplant Proc; 1999; 31(1-2):1214-5. PubMed ID: 10083542
[No Abstract] [Full Text] [Related]
26. Trough level-guided mycophenolate mofetil rejection prophylaxis in liver transplantation.
Grasser B; Iberer F; Schaffellner S; Kniepeiss D; Stauber R; Koshsorur G; Rehak P; Tscheliessnigg KH
Transplant Proc; 2001 May; 33(3):2154-6. PubMed ID: 11377484
[No Abstract] [Full Text] [Related]
27. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection.
Nicholls AJ
Clin Biochem; 1998 Jul; 31(5):329-33. PubMed ID: 9721430
[No Abstract] [Full Text] [Related]
28. Pharmacokinetic study of mycophenolate mofetil in Asian renal transplant recipients.
Yeung S; Tong KL; Tsang WK; Chan HW; Chan AY
Transplant Proc; 2000 Nov; 32(7):1753-4. PubMed ID: 11119920
[No Abstract] [Full Text] [Related]
29. Pharmacokinetics of mycophenolic acid after renal transplantation.
Wollenberg K; Krumme B; Schollmeyer P; Kirste G
Transplant Proc; 1998 Aug; 30(5):2237-9. PubMed ID: 9723455
[No Abstract] [Full Text] [Related]
30. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and CellCept in combination therapy.
Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
Transplant Proc; 1997; 29(1-2):334-6. PubMed ID: 9123027
[No Abstract] [Full Text] [Related]
31. Monitoring of mycophenolic acid in pediatric renal transplant recipients.
Armstrong VW; Shipkova M; Schütz E; Weber L; Tönshoff B; Oellerich M;
Transplant Proc; 2001; 33(1-2):1040-3. PubMed ID: 11267182
[No Abstract] [Full Text] [Related]
32. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ
Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic drug monitoring of mycophenolic acid can be used as predictor of clinical events for kidney transplant recipients treated with mycophenolate mofetil.
Lu YP; Zhu YC; Liang MZ; Nan F; Yu Q; Wang L; Wang J; Li YP
Transplant Proc; 2006 Sep; 38(7):2048-50. PubMed ID: 16979995
[TBL] [Abstract][Full Text] [Related]
34. Improved high-performance liquid chromatographic assay for the measurement of mycophenolic acid in human plasma.
Li S; Yatscoff RW
Transplant Proc; 1996 Apr; 28(2):938-40. PubMed ID: 8623471
[No Abstract] [Full Text] [Related]
35. Investigation of the crossreactivity of mycophenolic acid glucuronide metabolites and of mycophenolate mofetil in the Cedia MPA assay.
Shipkova M; Schütz E; Besenthal I; Fraunberger P; Wieland E
Ther Drug Monit; 2010 Feb; 32(1):79-85. PubMed ID: 20042920
[TBL] [Abstract][Full Text] [Related]
36. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation.
Bruce DS; Woodle ES; Newell KA; Millis JM; Cronin DC; Loss GE; Grewal HP; Siegel CT; Pellar S; Josephson MA; Thistlethwaite JR
Transplant Proc; 1998 Jun; 30(4):1538-40. PubMed ID: 9636625
[No Abstract] [Full Text] [Related]
37. Influence of renal graft function on mycophenolic acid pharmacokinetics during the early period after kidney transplant.
Mohammadpur AH; Nazemian F; Abtahi B; Naghibi M
Exp Clin Transplant; 2008 Dec; 6(4):276-81. PubMed ID: 19338489
[TBL] [Abstract][Full Text] [Related]
38. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
Vathsala A; Lu YM
Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
[No Abstract] [Full Text] [Related]
39. Pharmacokinetics of mycophenolate mofetil in heart transplant recipients.
Seebacher G; Mallinger R; Laufer G; Grimm M; Griesmacher A; Weigel G; Wolner E; Müller MM
Adv Exp Med Biol; 1998; 431():801-3. PubMed ID: 9598174
[No Abstract] [Full Text] [Related]
40. Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
Tedesco-Silva H; Felipe CR; Slade A; Schmouder RL; Medina Pestana JO
Ther Drug Monit; 2012 Dec; 34(6):652-9. PubMed ID: 23131696
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
